These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 18839776)
101. Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Rong L; Perelson AS Math Biosci; 2013 Sep; 245(1):22-30. PubMed ID: 23684949 [TBL] [Abstract][Full Text] [Related]
102. Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success. Cooper C Can J Gastroenterol; 2010 Jun; 24(6):385-90. PubMed ID: 20559582 [TBL] [Abstract][Full Text] [Related]
103. New therapies on the horizon for hepatitis C: are we close? De Francesco R; Rice CM Clin Liver Dis; 2003 Feb; 7(1):211-42, xi. PubMed ID: 12691468 [TBL] [Abstract][Full Text] [Related]
104. Structure-based design of hepatitis C virus inhibitors. Smith RM; Wu GY J Viral Hepat; 2003 Nov; 10(6):405-12. PubMed ID: 14633172 [TBL] [Abstract][Full Text] [Related]
105. Mixing the right hepatitis C inhibitor cocktail. Gelman MA; Glenn JS Trends Mol Med; 2011 Jan; 17(1):34-46. PubMed ID: 21106440 [TBL] [Abstract][Full Text] [Related]
107. Revolutionizing treatment outcomes in hepatitis C: managed care implications and considerations--a clinical overview. Shah M; Younossi ZM; Opsha Y Am J Manag Care; 2015 Mar; 21(5 Suppl):S76-85. PubMed ID: 26167957 [TBL] [Abstract][Full Text] [Related]
108. Future directions in the treatment of patients with chronic hepatitis C virus infection. Gish RG Can J Gastroenterol; 1999; 13(1):57-62. PubMed ID: 10099816 [TBL] [Abstract][Full Text] [Related]
109. [New Therapeutic Agent for Chronic Hepatitis C: Direct Acting Agent]. Chae HB Korean J Gastroenterol; 2015 Jul; 66(1):5-9. PubMed ID: 26194123 [TBL] [Abstract][Full Text] [Related]
110. Cytokines - their pathogenic and therapeutic role in chronic viral hepatitis. Larrubia JR; Benito-Martínez S; Miquel-Plaza J; Sanz-de-Villalobos E; González-Mateos F; Parra T Rev Esp Enferm Dig; 2009 May; 101(5):343-51. PubMed ID: 19527080 [TBL] [Abstract][Full Text] [Related]
111. Nanomedicine as a future therapeutic approach for Hepatitis C virus. Abd Ellah NH; Tawfeek HM; John J; Hetta HF Nanomedicine (Lond); 2019 Jun; 14(11):1471-1491. PubMed ID: 31166139 [TBL] [Abstract][Full Text] [Related]
112. Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Antonelli G; Scagnolari C; Moschella F; Proietti E Cytokine Growth Factor Rev; 2015 Apr; 26(2):121-31. PubMed ID: 25578520 [TBL] [Abstract][Full Text] [Related]
113. An update on the management of hepatitis C virus-related arthritis. Palazzi C; D'Amico E; D'Angelo S; Gilio M; Leccese P; Olivieri I Expert Opin Pharmacother; 2014 Oct; 15(14):2039-45. PubMed ID: 25146875 [TBL] [Abstract][Full Text] [Related]
114. [Treatment of chronic hepatitis C--new drugs, new hope]. Pawłowska M; Halota W Przegl Epidemiol; 2006; 60(4):725-30. PubMed ID: 17682754 [TBL] [Abstract][Full Text] [Related]
115. [Treatment of hepatitis C - an imminent revolution]. Schärer V; Bruggmann P; Müllhaupt B; Fehr J Praxis (Bern 1994); 2014 Sep; 103(19):1123-31. PubMed ID: 25228574 [TBL] [Abstract][Full Text] [Related]
116. Hepatitis C vaccine. Need of the hour. Verma R; Khanna P; Chawla S Hum Vaccin Immunother; 2014; 10(7):1927-9. PubMed ID: 25424801 [TBL] [Abstract][Full Text] [Related]
117. Revolutionizing treatment outcomes in hepatitis C: managed care implications and considerations--diagnosis and management. Shah M; Younossi ZM Am J Manag Care; 2015 Mar; 21(5 Suppl):S86-96. PubMed ID: 26167958 [TBL] [Abstract][Full Text] [Related]